My watch list  


Systematic (IUPAC) name
CAS number 54-96-6
ATC code  ?
PubChem  ?
Chemical data
Formula C5H7N3 
Mol. mass 109.13
Pharmacokinetic data
Bioavailability 30% [1],[2]
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status

Phase III

Routes Oral

3,4-Diaminopyridine is an experimental drug used in the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca2+ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate.

It has also been proposed for use in multiple sclerosis.[3]

See also

  • 4-Aminopyridine


  1. ^ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve 24: 1236-1238.
  2. ^ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.". Acta Neurol Scand 88: 136-140.
  3. ^ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224-59. PMID 16472864.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "3,4-Diaminopyridine". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE